The corporate will purchase Assertio Holdings for $23.5 per share in money, valuing the transaction at $166.4 million.
Assertio is a US-primarily based specialty pharmaceutical firm with a deal with oncology and ache administration. Zydus mentioned the acquisition aligns with its technique to strengthen its specialty oncology enterprise.
The transaction might be executed by a young supply, adopted by the merger of Zara, Zydus’ wholly-owned arm, into Assertio.
Put up-merger, Assertio will stay the surviving entity earlier than finally being delisted from the Nasdaq. The acquisition is anticipated to shut in FY27.
Assertio’s portfolio consists of Rolvedon, a most cancers therapy accredited by the USFDA underneath the Organic License Utility (BLA) pathway.
The corporate reported CY25 gross sales of $68.23 million, in comparison with $60.09 million a yr in the past.
Individually, Zydus Lifesciences will think about a proposal for the buyback of totally paid-up fairness shares on May 19, the identical day it declares its March quarter earnings.
This could mark the corporate’s third buyback in 4 years. In 2022, Zydus executed a ₹750 crore buyback, repurchasing 1.15 crore shares at ₹650 apiece.
In 2024, it carried out one other ₹600 crore buyback at ₹1,005 per share, involving 59.7 lakh shares. Each buybacks had been performed by the tender supply route, with promoter participation.
As of the March quarter, promoters held a 75% stake within the firm. Home mutual funds owned 4.88%, led by PPFAS and Kotak Mutual Fund, whereas Life Insurance coverage Company of India held a 5.56% stake. Overseas portfolio buyers owned 6.95%, whereas retail buyers held 4.8%.
Shares of Zydus Lifesciences ended 1% greater at ₹940 on Wednesday and are up 3% to this point in 2026.
First Revealed: May 14, 2026 6:48 AM IST
Source link
#Heres #today #important #sessions #Zydus #Life #shareholders #CNBC #TV18
